Hier finden Sie Publikationen unserer Mitarbeiter.

Letters in Drug Design & Discovery 8 (4): 302-307 (2011-05)

Fichtner I.; Behrens D.; Claffey J.; Deally A.; Gleeson B.; Patil S.; Weber H.; Tacke M.

The antiangiogenic and antitumoral activity of titanocene Y* in vivo

The 4-diethylaminomethylbenzyl-substituted titanocene dichloride (Titanocene Y*), which is completely water- soluble and showed nanomolar activity against the human renal cancer cells CAKI-1, was tested in vitro in an antiangiogenesis assay against human umbilical vein endothelial cells, HUVEC, delivering an IC50 value of 23 +/- 17 {Mu}M. Titanocene Y* was then given at 25, 50 and 75 mg/kg/d, on five consecutive days per week for up to three weeks to one cohort of six CAKI-1 tumor-bearing female NMRI:nu/nu mice, while a further cohort was treated with solvent only. At the two higher dosages Titanocene Y* showed high toxicity leading to mortality, while the titanocene-treated mouse cohort treated with the lowest dosage showed a moderate but statistically significant tumor growth reduction with respect to the solvent-treated control group, with an optimal T/C value of 76% at the end of the experiment. Immunohistological analysis revealed that the expression of the proliferation marker Ki-67 was reduced by 21%. Furthermore, anti-angiogenic activity was identified by CD31 staining; the number of micro vessels in a defined tumor area decreased by 23% due to Titanocene Y* treatment. The substance caused dose-dependent body weight loss but did not reduce the number of white blood cells at doses of 25 and 50 mg/kg/d.

Keywords: Tumor Area, Dichloride, Bevacizumab, Temsirolimus, Sorafenib, Sunitinib, Adenocarcinoma, Adult Malignancies, Adult Kidney, Malignant Disease, HUVEC, Xenograft, Renal Cell Cancer, Titanocene, Anti-Angiogenic Drug, Anticancer Drug

Type: Article

Official URL: https://doi.org/10.2174/157018011794839367
MDC Repository: https://edoc.mdc-berlin.de/12019/